---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000864673.md"
description: "$Moderna(MRNA.US)Moderna: Cancer Vaccine Changes the Game — But Don’t Chase the SpikeModerna’s 177% single-day surge followed a major breakthrough: its personalised mRNA cancer vaccine, intismeran, met the primary endpoint in a Phase 3 melanoma trial with Merck’s Keytruda, reducing recurrence and cancer spread. (Business Insider⁠)This is a genuine validation of personalised cancer vaccines. Earlier Phase 2b data showed a 49% reduction in recurrence/death risk and 59% reduction in distant metastasis/death over five years. (Merck.com⁠) However, detailed Phase 3 data and overall-survival results are still pending, so regulatory and commercial risks remain.Fundamentally, Moderna remains loss-making: Q2 revenue was only $100m, with a $800m net loss, although year-end cash guidance improved to $4.7–5.2bn. (Moderna Investors⁠) Valuation has consequently rerated dramatically, while technically the stock is severely extended after the historic gap-up.Outlook: HOLD — not Buy at this level. Accumulate only after consolidation or a substantial retracement.Option writers: favour 30–60 DTE cash-secured puts, targeting 15–25 delta, rather than chasing covered calls immediately. For bearish traders, consider 30–45 DTE calls around 15–20 delta, but only with defined risk.Not financial advice."
datetime: "2026-08-22T06:07:07.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000864673.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000864673.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000864673.md)
author: "[FaithAnchor](https://longbridge.com/en/profiles/24833348.md)"
generator: "portal-rs"
---

# $Moderna(MRNA.US)Moderna: Cancer Vaccine Changes t…


### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**